Blog Post
Stewardship Over Automation: FDA Redefines AI Accountability in Pharma
In reaction to the April 02, 2026 landmark FDA warning letter issued to Purolea Cosmetics Lab (MARCS-CMS 722591)[1], The Regulatory Mix[2] suggests that a trap...
Read More
Blog Post
Engaging Early: FDA’s Collaborative Pathways for AI in Regulatory Applications (Part 3 of 3)
Nick Armstrong, Senior Director of Digital Enablement at CAI and co-chair of the ISPE Community of Practice on AI, specializes in the intersection of artificial...
Read More